PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy

BACKGROUND: The rapid development of programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors has generated an urgent need for biomarkers assisting the selection of patients eligible for therapy. The use of PD-L1 immunohistochemistry, which has been suggested as a predictive biomarker,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Gevensleben, Heidrun, Holmes, Emily Eva, Goltz, Diane, Dietrich, Jörn, Sailer, Verena, Ellinger, Jörg, Dietrich, Dimo, Kristiansen, Glen
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346762/
https://ncbi.nlm.nih.gov/pubmed/27835597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13161
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky